Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...

"If immunotherapy eliminates most of the tumor before surgery, then we have sufficiently trained the immune system for an antitumor response, which minimizes the possibility of recurrence," said lead ...

Treatment with Bristol Myers Squibb's immunotherapies Opdivo and Yervoy prior to surgery for patients whose skin cancer had spread to lymph nodes had better outcomes than those who did not get the ...

Participants received 480 mg of nivolumab and 160 mg of relatlimab intravenously once every 4 weeks for two cycles before ...

Most patients with advanced melanoma treated with pre-surgical immunotherapy remained alive and free of disease four years post-treatment.

Depending on the disease specifics, patients with melanoma may undergo pre- or post-surgical therapies. Skin melanoma, one of the most serious forms of skin cancer, poses a significant threat to ...

Neoadjuvant targeted and immunotherapy in stage 3 melanoma showed significant pathologic responses, especially in BRAF-mutated cases, with 66.7% achieving major pathologic response. The trial ...

Melanoma treatment: Potential target bypasses therapeutic resistance to immune checkpoint blockers ... Support came from the UAB Department of Radiation Oncology and an O’Neal Invests Pre-R01 award; ...

The study of 423 patients with stage 3 melanoma found that 83.7% of patients who received the immunotherapies before their surgery were alive without the disease worsening after 12-months. The 12 ...